TY - GEN
T1 - Lambert-Eaton myasthenic syndrome
T2 - Tumor versus nontumor forms
AU - Titulaer, Maarten J.
AU - Verschuuren, Jan J.G.M.
PY - 2008/6
Y1 - 2008/6
N2 - Half the patients with Lambert-Eaton myasthenic syndrome (LEMS) have a small cell lung carcinoma (SCLC). SCLC is an aggressive tumor and survival is poor. We studied the differences between LEMS patients with and without an SCLC. Several items were identified, among which are age, smoking behavior, sex, the progression of clinical symptoms, HLA, and presence of Sox1 serum antibodies. The relationship between these parameters is not fully elucidated. Data support a role for the LEMS-related immune response in suppressing the tumor activity. We summarize the literature and present data from our Dutch cohort of 104 LEMS patients to compare the clinical and laboratory characteristics of tumor and nontumor related LEMS patients.
AB - Half the patients with Lambert-Eaton myasthenic syndrome (LEMS) have a small cell lung carcinoma (SCLC). SCLC is an aggressive tumor and survival is poor. We studied the differences between LEMS patients with and without an SCLC. Several items were identified, among which are age, smoking behavior, sex, the progression of clinical symptoms, HLA, and presence of Sox1 serum antibodies. The relationship between these parameters is not fully elucidated. Data support a role for the LEMS-related immune response in suppressing the tumor activity. We summarize the literature and present data from our Dutch cohort of 104 LEMS patients to compare the clinical and laboratory characteristics of tumor and nontumor related LEMS patients.
UR - http://www.scopus.com/inward/record.url?scp=45249120415&partnerID=8YFLogxK
U2 - 10.1196/annals.1405.030
DO - 10.1196/annals.1405.030
M3 - Conference proceeding
C2 - 18567862
AN - SCOPUS:45249120415
SN - 9781573316873
T3 - Annals of the New York Academy of Sciences
SP - 129
EP - 134
BT - Myasthenia Gravis and Related Disorders 11th International Conference
PB - Blackwell Publishing
ER -